Digital PCR (dPCR) and Real-time PCR (qPCR) Market in terms of revenue was estimated to be worth $10.0 billion in 2024 and is poised to reach $14.8 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

Growth in the digital PCR (dPCR) and real-time PCR (qPCR) market can be attributed to factors such as the rising incidence and prevalence of target infectious diseases and genetic disorders, continuous advancements in PCR technologies, the role of PCR in biomarker discovery, and increased use of dPCR and qPCR technologies for point of care (POC) diagnostics. However, challenges such as time consuming methodology involving in sample handling and post-PCR analysis, and lack of accuracy & standardization in protocol may hinder the market’s growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204

Browse in-depth TOC on “Digital PCR (dPCR) and Real-time PCR (qPCR) Market” 
502 – Tables 
47 – Figures
488 – Pages

Key Market Players:

The prominent players operating in the dPCR and qPCR market are Thermo Fisher Scientific (US), Danaher Corporation (US), and F. Hoffmann-La Roche, Ltd. (Switzerland).

Digital PCR (dPCR) and Real-time PCR (qPCR) Market Dynamics:

Drivers:

1. Rising incidence and prevalence of target infectious diseases and genetic disorders
2. Continuous advancements in PCR technologies
3. Growing importance of PCR in biomarker discovery

Restraints:

1. High device costs associated with dPCR
2. Technical limitations of qPCR and dPCR

Opportunities:

1. Growing market penetration in emerging countries

Challenges:

1. Time-consuming methodology involving sample handling and post-PCR analysis
2. Lack of accuracy & standardization in protocols

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=174151204

qPCR and dPCR reagents and consumables accounted for the largest share of global dPCR and qPCR market

Based on products & services, the qPCR market is categorized into reagents and consumables, instruments and software & services. The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products & services market in 2023. The dPCR and qPCR products are increasingly used by researchers and healthcare professionals due to the ongoing automation and miniaturization of qPCR/dPCR instruments, the commercialization of advanced software, and the availability of customized laboratory reagents. The increasing adoption of MIQE guidelines across the globe is also driving the use of qPCR/dPCR reagents among researchers. Expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), are expected to drive the growth of the reagents and consumables market.

Clinical application segment accounted for the largest share of qPCR market

Based on application, the qPCR and dPCR market is categorized into clinical applications (Infectious Disease Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and Other Clinical Applications), research applications, environmental applications, forensic applications and other applications. The clinical applications segment is estimated to dominate the Dpcr & qPCR applications market in 2022. The clinical applications segment is estimated to dominate the qPCR applications market during the forecast period. The key factors driving the market growth include the growing usage of qPCR in disease diagnosis, rising incidence of infectious and genetic diseases, and growing public emphasis on early & effective disease diagnosis & treatment.

The clinical applications segment is expected to account for the largest share of the digital PCR (dPCR) market in 2022. The technological benefits offered by dPCR over qPCR & traditional PCR (such as high flexibility, increased device sensitivity, better precision, and absolute quantification of target molecule), the growing adoption of dPCR among hospitals & diagnostic centers, and the increasing global burden of cancer & AIDS are key factors that will drive the market for clinical applications during the study period. The key factors driving the market growth of clinical applications segment include the growing usage of qPCR in disease diagnosis, rising incidence of infectious and genetic diseases, and growing public emphasis on early & effective disease diagnosis & treatment.

The hospitals and diagnostic laboratories is the largest and fastest growing end user segment of the qPCR & dpcr market

On the basis of end user, the dPCR and qPCR market is segmented into Hospitals and Diagnostic Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, CROs and CDMOs, Forensic Laboratories, and Other End Users. In 2022, the hospitals and diagnostic centers segment accounted for the largest share of the real-time PCR (qPCR) market. This can be attributed to the increasing market availability of qPCR reagents for clinical diagnostic applications, the ongoing expansion of healthcare infrastructure across emerging countries, the high prevalence of target diseases, and growing awareness among end users related to the benefits offered by qPCR for clinical diagnosis.

In 2022, the hospitals and diagnostic centers segment accounted for the largest share of the dPCR market. This can be attributed to the growing demand for early and efficient disease diagnosis and treatment, the increasing number of dPCR product launches for diagnostic applications, the benefits offered by dPCR in disease diagnosis (as compared to other PCR technologies), and the growing public awareness related to the benefits offered by dPCR in disease diagnosis.

North America accounted for the largest share of the dPCR and qPCR market

On the basis of region, In 2022, North America accounted for the largest share of the digital PCR (dPCR) and real-time PCR (qPCR) market, followed by Europe. The North American digital PCR (dPCR) and real-time PCR (qPCR) market is driven by the increased adoption of innovative and novel genomic analysis products (including advanced qPCR and dPCR products), availability of R&D funding for genomics research (coupled with the robust research infrastructure in the region), expanding use of PCR techniques in clinical diagnostics and forensics, and the early commercialization of qPCR/dPCR products in North America as compared to other regions.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=174151204

Recent Developments:

• In October 2022, Roche received FDA clearance for the COVID-19 PCR test for use on cobas 6800/8800 systems. The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high-throughput platform to receive FDA 510(k) clearance.
• In August 2022, Roche launched the Digital LightCycler System, Roche’s first digital polymerase chain reaction (PCR) system that will help clinical researchers better understand the nature of a patient’s cancer, genetic disease, or infection.
• In May 2022, QIAGEN (Netherlands) acquired BLIRT S.A. (Poland) which produces kits for the isolation of DNA and RNA, as well as reagents for reverse transcription and real-time PCR.
• In September 2021, Thermo Fisher Scientific launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.
• In June 2020, Cepheid Inc. received US FDA EUA for the Xpert Xpress SARS-CoV-2/Flu/RSV test.

Digital PCR (dPCR) and Real-time PCR (qPCR) Market Advantages:

• dPCR and qPCR are both very sensitive, allowing for detection and quantification of even trace amounts of DNA or RNA.
• dPCR and qPCR can both be used to determine the amount of specific genetic material present in a sample.
• dPCR and qPCR are both fast and efficient, allowing for rapid and accurate results.
• dPCR and qPCR can both be used to identify and quantify multiple targets in a single sample.
• dPCR and qPCR can both be used to detect mutations, SNPs, and other genetic variations.
• dPCR and qPCR are both cost-effective, making them ideal for use in clinical and research applications.
• dPCR and qPCR can both be used to monitor gene expression, allowing for the identification of differentially expressed genes.